We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Bicycle Therapeutics plc (BCYC) ADS REP 1 SHS SPON

Sell:$22.60 Buy:$22.66 Change: $0.45 (2.03%)
NASDAQ:0.63%
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Sell:$22.60
Buy:$22.66
Change: $0.45 (2.03%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Sell:$22.60
Buy:$22.66
Change: $0.45 (2.03%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

Contact details

Address:
Blocks A & B, Portway Building, Granta P
CAMBRIDGE
CB21 6GS
United Kingdom
Telephone:
+44 (1223) 261503
Website:
https://www.bicycletherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BCYC
ISIN:
US0887861088
Market cap:
$1.04 billion
Shares in issue:
42.78 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Kevin Lee
    Chief Executive Officer, Executive Director
  • Alethia Young
    Chief Financial Officer, Principal Financial Officer
  • Alistair Milnes
    Chief Operating Officer
  • Michael Skynner
    Chief Technology Officer
  • Travis Thompson
    Chief Accounting Officer, Principal Accounting Officer
  • Nicholas Keen
    Chief Scientific Officer
  • Santiago Arroyo
    Chief Development Officer
  • Nigel Crockett
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.